InflaRx IFRX 深 沪
等待开盘 12-18 09:30:00 美东时间
1.01
-0.030
-2.88%
华盛通- 最 高1.12
- 今 开1.04
- 成交量 63.57万股
- 最 低 1.01
- 昨 收 1.04
- 总市值 6842.46万
- 52周最高 2.77
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 0.7113
- 委 比 -58.04%
- 总股本 6774.71万
- 历史最高 53.10
- 量 比 1.06
- 振 幅 10.58%
- 历史最低 0.7113
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
InflaRx N.V. announced that the WHO granted the INN name "izicopan" to its orally available C5aR inhibitor, formerly INF904. CEO Prof. Niels C. Riedemann highlighted the promising clinical data in hidradenitis suppurativa and chronic spontaneous urticaria, showcasing izicopan's potential to address significant unmet needs in both diseases. Izicopan, an oral C5aR inhibitor, has demonstrated best-in-class potential with favorable safety and efficac...
12-11 12:30
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 28.9% to $1.22 during Friday's pre-mar...
12-05 20:05
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Leerink Partners Downgrades InflaRx to Market Perform, Lowers Price Target to $2
Leerink Partners analyst Joseph Schwartz downgrades InflaRx (NASDAQ:IFRX) from Outperform to Market Perform and lowers the price target from $5 to $2.
12-03 21:37
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers enGene Holdings (NASDAQ:ENGN) stock moved upwards by 3.5% to $7.12 dur...
11-19 05:06
美股牛股 | COGT飙升近120%！在治疗胃肠道间质瘤领域取得重大突破，拟向FDA提交新药申请；纳微半导体大涨超22%
COGT飙升近120%！在治疗胃肠道间质瘤领域取得重大突破，拟向FDA提交新药申请；纳微半导体大涨超22%，获分析师上调目标价至13美元>>>>
11-11 14:55
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Guggenheim Maintains Buy on InflaRx, Raises Price Target to $22
Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $10 to $22.
11-10 21:12
InflaRx To Present Data From Phase 2a Clinical Study Of Oral C5ar Inhibitor INF904 In Participants With Hidradenitis Suppurativa And Chronic Spontaneous Urticaria On Nov. 10
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report topline data from the Phase 2a clinical
11-08 05:07
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
Edesa Biotech (($EDSA)), Inflarx N.V. (($IFRX)) announced an update on their on...
10-28 07:50
